Instrument Inactif

Autres langues Abbott Laboratories Cinnober Boat

Actions

ABT

US0028241000

Equipement, fournitures et distribution médicale

Autres langues

30/09	Abbott Launches Simplescreen Crc Blood Test in the U.S
30/09	Abbott Launches SimpleScreen Blood Test for Colorectal Cancer
30/09	Abbott hosts conference call for third-quarter earnings
30/09	Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
25/09	Abbott Laboratories : Landmark study in people with Type 2 diabetes using basal insulin shows continuous glucose monitoring, including Abbott’s Libre technology, associated with lower risk of death and cardiovascular complications
24/09	US FDA advisers endorse Grail cancer test's benefits in key vote
23/09	Abbott and Berry Street team up on personalized nutrition tracking
23/09	US companies face rise in cyber attacks
23/09	Abbott and Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
23/09	Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
21/09	Grail rallies as FDA staff flags no major concerns for multi-cancer test
18/09	Trinity Heart Experts First in the Quad Cities to Use New Afib Technology
17/09	Abbott Laboratories Declares Quarterly Dividend, Payable on Nov. 16, 2026
17/09	Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Nov. 16 to Holders of Record on Oct. 15
17/09	Abbott declares 411th consecutive quarterly dividend
15/09	Abbott Announces First Canadian Use of Volt Pulsed Field Ablation System to Treat Atrial Fibrillation
15/09	First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
15/09	Abbott to pay $385M over infant formula contamination probe
14/09	Abbott agrees to settlement over closure of largest baby formula plant in the US
14/09	Abbott Laboratories to Pay $385 Million to Settle Infant Formula Allegations
14/09	Abbott to Pay $385 Million to Resolve Baby Formula Contamination Claims
14/09	Abbott to pay $384 million over contaminated infant formula allegations, US Justice Dept says
14/09	Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
08/09	Abbott Receives FDA Approval for Device to Treat Abnormal Heart Rhythm
08/09	Abbott Receives FDA Approval for TactiFlex Duo Ablation Catheter to Treat Abnormal Heart Rhythms